Free Trial
→ Gold Hits New Highs as Global Markets Spiral (From Premier Gold Co) (Ad) Buy IDYA Stock  Free IDYA Stock Alerts

IDEAYA Biosciences (IDYA) Financials

IDEAYA Biosciences logo
$19.63 +1.55 (+8.57%)
As of 05/20/2025 04:00 PM Eastern
Compare
Annual Income Statements for IDEAYA Biosciences

Annual Income Statements for IDEAYA Biosciences

This table shows IDEAYA Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Income / (Loss) Attributable to Common Shareholders		 -274 -113 -59 -50 -35 -42 -34
Consolidated Net Income / (Loss)		 -274 -113 -59 -50 -34 -42 -34
Net Income / (Loss) Continuing Operations		 -274 -113 -59 -50 -34 -42 -34
Total Pre-Tax Income 		-327 -134 -63 -50 -35 -44 -36
Total Operating Income		 -327 -134 -63 -50 -35 -44 -36
Total Gross Profit		 7.00 23 51 28 20 0.00 0.00
Total Revenue		 7.00 23 51 28 20 0.00 0.00
Operating Revenue		 7.00 23 51 28 20 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 334 158 113 78 55 44 36
Selling, General & Admin Expense		 39 28 24 20 15 9.95 4.67
Research & Development Expense		 295 130 90 58 40 34 32
Total Other Income / (Expense), net		 0.00 0.00 0.00 0.51 0.00 0.00 0.00
Other Gains / (Losses), net		 52 21 3.85 - 0.85 2.30 2.07
Basic Earnings per Share		 ($3.36) ($1.96) ($1.42) ($1.41) ($1.40) ($3.36) ($35.92)
Weighted Average Basic Shares Outstanding		 81.68M 57.52M 41.44M 35.25M 24.72M 12.50M 956.25K
Diluted Earnings per Share		 ($3.36) ($1.96) ($1.42) ($1.41) ($1.40) ($3.36) ($35.92)
Weighted Average Diluted Shares Outstanding		 81.68M 57.52M 41.44M 35.25M 24.72M 12.50M 956.25K
Weighted Average Basic & Diluted Shares Outstanding		 87.54M 74.56M 48.39M 35.25M 24.72M 12.50M 956.25K

Quarterly Income Statements for IDEAYA Biosciences

This table shows IDEAYA Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -72 -135 -47 -53 -40 -35 -27 -28 -24 -24 1.62
Consolidated Net Income / (Loss)		 -72 -130 -52 -53 -40 -34 -27 -28 -24 -24 1.62
Net Income / (Loss) Continuing Operations		 -72 -130 -52 -53 -40 -34 -27 -28 -24 -24 1.62
Total Pre-Tax Income 		-72 -156 -67 -65 -40 -45 -34 -33 -24 -28 1.62
Total Operating Income		 -84 -144 -67 -65 -51 -42 -34 -33 -26 -26 0.66
Total Gross Profit		 0.00 7.00 0.00 0.00 0.00 3.92 8.04 3.54 7.88 4.02 30
Total Revenue		 0.00 7.00 0.00 0.00 0.00 3.92 8.04 3.54 7.88 4.02 30
Operating Revenue		 0.00 7.00 0.00 0.00 0.00 3.92 8.04 3.54 7.88 4.02 30
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 84 151 67 65 51 46 42 36 34 30 29
Selling, General & Admin Expense		 14 11 9.74 10 8.21 7.07 7.86 7.08 6.30 5.75 6.67
Research & Development Expense		 71 140 57 55 43 39 34 29 28 25 22
Total Other Income / (Expense), net		 12 -11 0.00 0.00 11 -2.64 0.00 0.00 2.64 -1.40 0.96
Other Income / (Expense), net		 12 - - - 11 - - - 2.64 - -
Basic Earnings per Share		 ($0.82) ($1.55) ($0.60) ($0.68) ($0.53) ($0.51) ($0.46) ($0.50) ($0.49) ($0.53) $0.04
Weighted Average Basic Shares Outstanding		 88.36M 81.68M 86.19M 77.96M 75.11M 57.52M 60.00M 56.25M 48.37M 41.44M 40.30M
Diluted Earnings per Share		 ($0.82) ($1.55) ($0.60) ($0.68) ($0.53) ($0.51) ($0.46) ($0.50) ($0.49) ($0.53) $0.04
Weighted Average Diluted Shares Outstanding		 88.36M 81.68M 86.19M 77.96M 75.11M 57.52M 60.00M 56.25M 48.37M 41.44M 41.11M
Weighted Average Basic & Diluted Shares Outstanding		 87.58M 87.54M 86.43M 84.48M 75.69M 74.56M 64.46M 57.56M - 48.39M 48.11M

Annual Cash Flow Statements for IDEAYA Biosciences

This table details how cash moves in and out of IDEAYA Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Change in Cash & Equivalents		 -73 89 -23 20 38 14 15
Net Cash From Operating Activities		 -248 -115 -87 -56 55 -39 -28
Net Cash From Continuing Operating Activities		 -248 -115 -87 -56 55 -39 -28
Net Income / (Loss) Continuing Operations		 -274 -113 -59 -50 -34 -42 -34
Consolidated Net Income / (Loss)		 -274 -113 -59 -50 -34 -42 -34
Depreciation Expense		 2.39 2.48 2.10 1.73 1.38 1.25 0.89
Amortization Expense		 -22 -10 0.72 3.14 0.58 -0.47 -0.81
Non-Cash Adjustments To Reconcile Net Income		 35 4.74 -35 -15 3.59 3.27 4.99
Changes in Operating Assets and Liabilities, net		 12 0.55 3.51 4.42 84 -1.38 1.65
Net Cash From Investing Activities		 -503 -158 -33 -70 -146 2.27 -63
Net Cash From Continuing Investing Activities		 -503 -158 -33 -70 -146 2.27 -63
Purchase of Property, Plant & Equipment		 -3.86 -2.37 -3.44 -2.64 -0.49 -1.35 -1.71
Purchase of Investments		 -1,191 -596 -256 -315 -242 -88 -133
Sale and/or Maturity of Investments		 693 440 226 248 97 92 72
Net Cash From Financing Activities		 678 363 97 145 129 51 105
Net Cash From Continuing Financing Activities		 678 363 97 145 129 51 105
Issuance of Common Equity		 665 353 96 144 128 50 0.00
Other Financing Activities, net		 12 9.56 1.45 1.50 1.19 0.29 0.09
Cash Interest Paid		 0.03 0.07 0.06 0.07 0.08 0.09 0.10
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for IDEAYA Biosciences

This table details how cash moves in and out of IDEAYA Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 46 -316 217 75 -49 5.20 49 36 -1.40 -33 53
Net Cash From Operating Activities		 -60 -122 -49 -33 -44 -24 -30 -33 -28 -23 -24
Net Cash From Continuing Operating Activities		 -60 -122 -49 -33 -44 -24 -30 -33 -28 -23 -24
Net Income / (Loss) Continuing Operations		 -72 -130 -52 -53 -40 -34 -27 -28 -24 -24 1.62
Consolidated Net Income / (Loss)		 -72 -130 -52 -53 -40 -34 -27 -28 -24 -24 1.62
Depreciation Expense		 0.60 0.57 0.58 0.62 0.62 0.63 0.64 0.62 0.59 0.56 0.57
Amortization Expense		 -3.25 -4.85 -4.93 -6.17 -5.85 -3.48 -3.18 -2.18 -1.19 -0.76 0.27
Non-Cash Adjustments To Reconcile Net Income		 10 9.49 9.22 9.73 6.31 -8.96 5.30 4.73 3.66 -44 3.01
Changes in Operating Assets and Liabilities, net		 4.24 3.45 -2.28 16 -5.32 22 -5.50 -8.71 -7.26 45 -30
Net Cash From Investing Activities		 80 -197 -20 69 -354 -112 51 -121 24 -10 -19
Net Cash From Continuing Investing Activities		 80 -197 -20 69 -354 -112 51 -121 24 -10 -19
Purchase of Property, Plant & Equipment		 -1.33 -1.10 -0.46 -0.97 -1.33 -0.84 -0.60 -0.88 -0.04 - -1.10
Purchase of Investments		 -105 -337 -214 -165 -476 -222 -82 -220 -72 -66 -88
Sale and/or Maturity of Investments		 186 141 194 234 123 111 134 100 96 55 71
Net Cash From Financing Activities		 26 2.75 287 39 349 141 28 191 2.93 0.32 96
Net Cash From Continuing Financing Activities		 26 2.75 287 39 349 141 28 191 2.93 0.32 96
Issuance of Common Equity		 25 0.25 284 37 344 135 26 190 2.56 -0.19 95
Other Financing Activities, net		 1.13 2.50 2.44 2.08 5.46 5.85 1.86 1.49 0.37 0.52 0.50
Cash Interest Paid		 0.00 - 0.00 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.01

Annual Balance Sheets for IDEAYA Biosciences

This table presents IDEAYA Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Total Assets		 1,124 649 388 381 298 113 97
Total Current Assets		 690 533 370 251 289 102 91
Cash & Equivalents		 84 157 69 92 72 34 21
Short-Term Investments		 592 368 296 155 212 65 69
Accounts Receivable		 0.00 0.02 0.21 1.10 1.88 0.00 -
Prepaid Expenses		 13 7.50 5.41 3.12 3.14 2.70 0.71
Plant, Property, & Equipment, net		 8.97 6.16 6.51 4.76 4.27 4.64 5.15
Total Noncurrent Assets		 425 111 11 126 5.39 6.71 0.72
Long-Term Investments		 406 107 8.32 121 0.00 1.53 -
Other Noncurrent Operating Assets		 20 3.03 2.69 4.30 5.39 5.18 0.72
Total Liabilities & Shareholders' Equity		 1,124 649 388 381 298 113 97
Total Liabilities		 65 28 39 80 100 13 7.10
Total Current Liabilities		 46 27 32 45 39 6.94 5.41
Accounts Payable		 15 6.60 4.28 2.10 0.95 0.71 1.42
Accrued Expenses		 30 19 17 12 8.52 5.02 3.58
Current Deferred Revenue		 0.00 0.00 8.57 29 28 0.00 0.30
Other Current Liabilities		 0.30 1.75 1.87 1.70 1.56 1.21 0.11
Total Noncurrent Liabilities		 19 1.13 6.80 35 61 5.66 1.69
Noncurrent Deferred Revenue		 0.00 0.00 5.19 31 56 0.00 1.57
Other Noncurrent Operating Liabilities		 19 1.13 1.61 3.48 5.20 5.66 0.11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,059 621 349 302 198 100 -49
Total Preferred & Common Equity		 1,059 621 349 302 198 100 -49
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,059 621 349 302 198 100 -49
Common Stock		 1,681 969 588 479 325 193 1.60
Retained Earnings		 -623 -348 -235 -177 -127 -92 -51
Accumulated Other Comprehensive Income / (Loss)		 0.81 0.56 -2.87 -0.71 0.01 0.07 -0.03

Quarterly Balance Sheets for IDEAYA Biosciences

This table presents IDEAYA Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,101 1,240 974 962 533 528 365 411
Total Current Assets		 708 932 713 709 482 502 344 393
Cash & Equivalents		 130 400 183 108 152 103 67 102
Short-Term Investments		 563 520 519 590 317 391 272 284
Accounts Receivable		 0.00 0.02 0.00 0.02 6.70 0.16 0.47 3.45
Prepaid Expenses		 15 12 12 11 6.73 7.91 4.02 3.74
Plant, Property, & Equipment, net		 8.87 8.24 7.12 6.91 6.19 6.83 6.72 6.68
Total Noncurrent Assets		 384 299 253 245 45 19 14 11
Long-Term Investments		 359 280 251 243 42 16 12 7.69
Other Noncurrent Operating Assets		 25 19 2.29 2.63 2.17 2.56 2.33 3.10
Total Liabilities & Shareholders' Equity		 1,101 1,240 974 962 533 528 365 411
Total Liabilities		 77 59 42 26 25 26 31 42
Total Current Liabilities		 51 41 41 25 25 25 30 33
Accounts Payable		 18 13 16 6.29 5.17 5.87 4.38 3.65
Accrued Expenses		 33 28 24 18 16 15 17 17
Other Current Liabilities		 0.31 0.00 0.61 1.15 2.10 1.96 1.92 1.83
Total Noncurrent Liabilities		 26 19 1.26 1.26 0.00 0.61 1.12 9.41
Other Noncurrent Operating Liabilities		 26 19 1.26 1.26 0.00 0.61 1.12 2.10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,024 1,180 932 935 508 502 334 369
Total Preferred & Common Equity		 1,024 1,180 932 935 508 502 334 369
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,024 1,180 932 935 508 502 334 369
Common Stock		 1,718 1,669 1,374 1,324 823 790 594 584
Retained Earnings		 -695 -493 -441 -388 -314 -287 -259 -211
Accumulated Other Comprehensive Income / (Loss)		 1.59 3.84 -1.42 -0.92 -0.75 -1.18 -1.41 -4.00

Annual Metrics And Ratios for IDEAYA Biosciences

This table displays calculated financial ratios and metrics derived from IDEAYA Biosciences' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Growth Metrics		 - - - - - - -
Revenue Growth		 -70.07% -54.08% 82.28% 43.01% 0.00% 0.00% 0.00%
EBITDA Growth		 -143.97% -137.88% -32.93% -34.48% 23.25% -19.70% 0.00%
EBIT Growth		 -143.23% -115.08% -25.60% -40.79% 20.16% -21.57% 0.00%
NOPAT Growth		 -143.23% -115.08% -24.34% -42.23% 20.16% -21.57% 0.00%
Net Income Growth		 -142.98% -92.59% -17.87% -44.26% 17.82% -22.21% 0.00%
EPS Growth		 -71.43% -38.03% -0.71% -0.71% 58.33% 90.65% 0.00%
Operating Cash Flow Growth		 -114.87% -32.18% -56.29% -200.57% 241.08% -42.34% 0.00%
Free Cash Flow Firm Growth		 -104.56% -22.71% -60.54% -189.19% 292.48% 0.00% 0.00%
Invested Capital Growth		 -99.76% 51.39% 64.40% 21.99% -103,937.80% 84.17% 0.00%
Revenue Q/Q Growth		 78.43% -0.42% 2.13% -21.40% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -42.70% -14.63% -19.01% -36.93% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 -45.48% -13.01% -14.83% -33.84% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -45.48% -13.01% -14.83% -35.21% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 -54.10% -9.45% -11.37% -35.65% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 -44.83% 1.01% -2.90% -45.36% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -65.41% -0.33% -8.34% -9.98% -4.95% -3.23% 0.00%
Free Cash Flow Firm Q/Q Growth		 -54.53% -0.89% -6.83% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -16.54% -271.96% 5.86% 2.33% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -4,948.20% -607.12% -117.18% -160.68% -170.87% 0.00% 0.00%
Operating Margin		 -4,671.07% -574.85% -122.72% -179.91% -180.90% 0.00% 0.00%
EBIT Margin		 -4,671.07% -574.85% -122.72% -178.10% -180.90% 0.00% 0.00%
Profit (Net Income) Margin		 -3,921.10% -483.05% -115.17% -178.10% -176.55% 0.00% 0.00%
Tax Burden Percent		 83.94% 84.03% 93.85% 100.00% 97.60% 94.81% 94.31%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.67% -23.28% -18.02% -19.91% -23.10% -44.22% -38.40%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -36.88% -25.92% -16.25% -14.64% -17.19% 0.00% 0.00%
Return on Assets (ROA)		 -30.95% -21.78% -15.25% -14.64% -16.77% 0.00% 0.00%
Return on Common Equity (ROCE)		 -32.67% -23.28% -18.02% -19.91% -23.10% -11.98% 21.01%
Return on Equity Simple (ROE_SIMPLE)		 -25.91% -18.19% -16.78% -16.50% -17.40% -41.81% 70.17%
Net Operating Profit after Tax (NOPAT)		 -229 -94 -44 -35 -25 -31 -25
NOPAT Margin		 -3,269.75% -402.40% -85.90% -125.94% -126.63% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.32% -3.75% -4.02% -4.47% -5.08% -11.54% -9.84%
Return On Investment Capital (ROIC_SIMPLE)		 -21.61% -15.15% -12.52% - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 561.46% 121.04% 46.92% 71.76% 77.72% 0.00% 0.00%
R&D to Revenue		 4,209.61% 553.81% 175.80% 208.15% 203.18% 0.00% 0.00%
Operating Expenses to Revenue		 4,771.07% 674.85% 222.72% 279.91% 280.90% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -327 -134 -63 -50 -35 -44 -36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -346 -142 -60 -45 -33 -43 -36
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 2.10 3.69 2.50 3.02 2.05 1.52 0.00
Price to Tangible Book Value (P/TBV)		 2.10 3.69 2.50 3.02 2.05 1.52 0.00
Price to Revenue (P/Rev)		 317.33 98.07 17.16 32.57 20.83 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 162.74 71.02 9.84 19.40 6.32 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 2.22 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 2.04 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.04 -1.14 -1.30 -1.29 -1.00 -1.01
Leverage Ratio		 1.06 1.07 1.18 1.36 1.38 1.10 1.08
Compound Leverage Factor		 1.06 1.07 1.18 1.36 1.38 1.10 1.08
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 154.73%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -54.73%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 19.48 48.29 13.42 6.48 2.53 5.83 3.31
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 72.90% 154.73%
Liquidity Ratios		 - - - - - - -
Current Ratio		 14.97 19.65 11.68 5.56 7.47 14.65 16.75
Quick Ratio		 14.68 19.38 11.51 5.49 7.39 14.26 16.62
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 -217 -106 -87 -54 60 -31 0.00
Operating Cash Flow to CapEx		 -6,419.08% -4,865.88% -2,531.95% -2,109.64% 11,250.10% -2,905.62% -1,617.10%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.01 0.05 0.13 0.08 0.10 0.00 0.00
Accounts Receivable Turnover		 666.67 204.24 77.52 18.75 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.93 3.69 9.04 6.19 4.38 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.55 1.79 4.71 19.46 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.55 1.79 4.71 19.46 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -23 -12 -24 -67 -85 -0.08 -0.52
Invested Capital Turnover		 -0.41 -1.33 -1.13 -0.37 -0.46 0.00 0.00
Increase / (Decrease) in Invested Capital		 -11 12 43 19 -85 0.44 0.00
Enterprise Value (EV)		 1,139 1,661 501 542 123 52 98
Market Capitalization		 2,221 2,293 874 910 407 152 50
Book Value per Share		 $12.25 $9.64 $7.26 $7.83 $6.82 $4.94 ($51.19)
Tangible Book Value per Share		 $12.25 $9.64 $7.26 $7.83 $6.82 $4.94 ($51.19)
Total Capital		 1,059 621 349 302 198 100 89
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,082 -633 -373 -368 -284 -100 -90
Capital Expenditures (CapEx)		 3.86 2.37 3.44 2.64 0.49 1.35 1.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -33 -20 -26 -41 -34 -4.24 -4.71
Debt-free Net Working Capital (DFNWC)		 644 506 339 206 250 95 85
Net Working Capital (NWC)		 644 506 339 206 250 95 85
Net Nonoperating Expense (NNE)		 46 19 15 15 9.75 11 8.85
Net Nonoperating Obligations (NNO)		 -1,082 -633 -373 -368 -284 -100 -90
Total Depreciation and Amortization (D&A)		 -19 -7.55 2.82 4.87 1.96 0.77 0.08
Debt-free, Cash-free Net Working Capital to Revenue		 -466.81% -83.74% -51.23% -146.50% -172.07% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 9,194.89% 2,161.77% 665.09% 736.68% 1,279.38% 0.00% 0.00%
Net Working Capital to Revenue		 9,194.89% 2,161.77% 665.09% 736.68% 1,279.38% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 ($3.36) ($1.96) ($1.42) ($1.41) ($1.40) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 81.68M 57.52M 41.44M 38.63M 32.26M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($3.36) ($1.96) ($1.42) ($1.41) ($1.40) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 81.68M 57.52M 41.44M 38.63M 32.26M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.41) ($1.40) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 87.54M 74.56M 48.39M 35.25M 24.72M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -229 -94 -44 -35 -25 -31 -25
Normalized NOPAT Margin		 -3,269.75% -402.40% -85.90% -125.94% -126.63% 0.00% 0.00%
Pre Tax Income Margin		 -4,671.07% -574.85% -122.72% -178.10% -180.90% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for IDEAYA Biosciences

This table displays calculated financial ratios and metrics derived from IDEAYA Biosciences' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 78.43% -100.00% -100.00% -100.00% -2.46% -72.94% -39.43% -30.63% 35.79% 230.87%
EBITDA Growth		 -33.02% -231.52% -97.54% -105.66% -84.86% -67.99% -2,506.00% -62.96% -85.54% -55.69% 114.50%
EBIT Growth		 -41.48% -243.88% -99.53% -98.50% -67.39% -58.51% -5,179.70% -48.30% -66.24% -43.95% 105.70%
NOPAT Growth		 -65.41% -243.88% -99.53% -98.50% -94.14% -58.51% -3,655.79% -45.38% -84.80% -43.95% 108.05%
Net Income Growth		 -82.40% -283.78% -88.85% -88.97% -67.39% -40.30% -1,799.07% -26.61% -68.70% -32.88% 113.94%
EPS Growth		 -54.72% -203.92% -30.43% -36.00% -8.16% 3.77% -1,250.00% 12.28% -36.11% -8.16% 112.90%
Operating Cash Flow Growth		 -37.73% -412.27% -63.17% 1.73% -57.36% -1.62% -24.86% -67.37% -41.71% -40.30% -93.82%
Free Cash Flow Firm Growth		 18.90% -115.36% 33.72% 52.29% 19.71% 32.35% -7.62% -105.93% -97.36% -94.08% -26.41%
Invested Capital Growth		 -343.46% -99.76% -537.56% -148.36% 64.96% 51.39% 87.70% 84.42% 69.77% 64.40% 63.07%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% -100.00% -51.19% 126.81% -55.03% 95.92% -86.46% 407.59%
EBITDA Q/Q Growth		 49.58% -108.31% -1.10% -57.29% -0.08% -24.13% -5.26% -41.37% 9.05% -1,877.72% 107.13%
EBIT Q/Q Growth		 49.92% -115.48% -3.03% -64.07% 5.59% -25.02% -2.50% -38.36% 10.60% -4,106.52% 102.99%
NOPAT Q/Q Growth		 41.45% -115.48% -3.03% -27.27% -21.72% -25.02% -2.50% -24.47% 0.62% -2,904.56% 104.19%
Net Income Q/Q Growth		 44.61% -151.47% 1.80% -33.36% -16.54% -23.74% 1.74% -18.13% 2.32% -1,598.51% 107.32%
EPS Q/Q Growth		 47.10% -158.33% 11.76% -28.30% -3.92% -10.87% 8.00% -2.04% 7.55% -1,425.00% 107.02%
Operating Cash Flow Q/Q Growth		 50.40% -147.10% -49.73% 24.95% -84.49% 21.30% 9.82% -20.18% -19.14% 3.29% -20.88%
Free Cash Flow Firm Q/Q Growth		 57.35% -196.23% 8.15% 30.10% -13.25% 8.83% 33.89% -17.64% 4.58% -45.03% -26.50%
Invested Capital Q/Q Growth		 -17.54% -16.54% 6.32% -245.60% 47.06% -271.96% 63.51% 51.24% 26.55% 5.86% 53.80%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -2,120.16% 0.00% 0.00% 0.00% -1,141.14% -448.69% -966.85% -307.58% -662.56% 5.05%
Operating Margin		 0.00% -2,059.11% 0.00% 0.00% 0.00% -1,068.44% -417.09% -922.94% -333.49% -657.46% 2.22%
EBIT Margin		 0.00% -2,059.11% 0.00% 0.00% 0.00% -1,068.44% -417.09% -922.94% -300.00% -657.46% 2.22%
Profit (Net Income) Margin		 0.00% -1,861.60% 0.00% 0.00% 0.00% -865.54% -341.38% -787.98% -300.00% -601.72% 5.44%
Tax Burden Percent		 100.00% 83.76% 77.47% 81.28% 100.00% 76.21% 81.85% 85.38% 100.00% 86.93% 100.00%
Interest Burden Percent		 100.00% 107.94% 100.00% 100.00% 100.00% 106.30% 100.00% 100.00% 100.00% 105.29% 244.70%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -31.34% -32.67% -21.10% -21.45% -20.31% -23.28% -23.54% -19.24% -21.94% -18.02% -15.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -16.26% 0.00% 0.00% 0.00% -48.17% -20.76% -96.28% -39.35% -87.05% 0.27%
Return on Assets (ROA)		 0.00% -14.70% 0.00% 0.00% 0.00% -39.03% -16.99% -82.20% -39.35% -79.67% 0.67%
Return on Common Equity (ROCE)		 -31.34% -32.67% -21.10% -21.45% -20.31% -23.28% -23.54% -19.24% -21.94% -18.02% -15.35%
Return on Equity Simple (ROE_SIMPLE)		 -29.98% 0.00% -15.09% -16.50% -13.78% 0.00% -20.31% -14.78% -20.46% 0.00% -14.28%
Net Operating Profit after Tax (NOPAT)		 -59 -101 -47 -45 -36 -29 -23 -23 -18 -19 0.66
NOPAT Margin		 0.00% -1,441.38% 0.00% 0.00% 0.00% -747.91% -291.97% -646.06% -233.44% -460.22% 2.22%
Net Nonoperating Expense Percent (NNEP)		 -1.32% -3.43% -0.58% -1.00% -0.60% -0.92% -0.88% -1.21% -1.50% -1.54% 0.25%
Return On Investment Capital (ROIC_SIMPLE)		 -5.77% -9.53% - - - -4.72% - - - -5.30% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 156.50% 0.00% 0.00% 0.00% 180.17% 97.82% 199.63% 79.95% 143.04% 22.45%
R&D to Revenue		 0.00% 2,002.61% 0.00% 0.00% 0.00% 988.27% 419.27% 823.31% 353.54% 614.42% 75.33%
Operating Expenses to Revenue		 0.00% 2,159.11% 0.00% 0.00% 0.00% 1,168.44% 517.09% 1,022.94% 433.49% 757.46% 97.78%
Earnings before Interest and Taxes (EBIT)		 -72 -144 -67 -65 -40 -42 -34 -33 -24 -26 0.66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -75 -148 -71 -70 -45 -45 -36 -34 -24 -27 1.50
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.40 2.10 2.27 2.85 3.02 3.69 3.06 2.27 1.99 2.50 1.59
Price to Tangible Book Value (P/TBV)		 1.40 2.10 2.27 2.85 3.02 3.69 3.06 2.27 1.99 2.50 1.59
Price to Revenue (P/Rev)		 204.84 317.33 682.23 222.17 182.42 98.07 66.13 25.19 14.00 17.16 11.76
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 54.67 162.74 376.30 142.52 121.71 71.02 44.36 13.89 6.60 9.84 3.86
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.01 -1.02 -1.02 -1.04 -1.03 -1.08 -1.12 -1.14 -1.14
Leverage Ratio		 1.05 1.06 1.05 1.05 1.05 1.07 1.08 1.12 1.16 1.18 1.18
Compound Leverage Factor		 1.05 1.14 1.05 1.05 1.05 1.14 1.08 1.12 1.16 1.24 2.89
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 10.87 20.02 27.14 37.95 64.90 48.76 37.47 26.50 12.84 13.72 8.81
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.92 14.97 22.93 17.50 28.42 19.65 19.37 19.80 11.53 11.68 12.02
Quick Ratio		 13.62 14.68 22.63 17.22 28.00 19.38 19.10 19.49 11.40 11.51 11.91
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -38 -89 -30 -33 -47 -42 -46 -69 -59 -61 -42
Operating Cash Flow to CapEx		 -4,536.99% -11,039.47% -10,773.30% -3,379.45% -3,306.64% -2,833.89% -5,003.98% -3,785.07% -64,748.84% 0.00% -2,194.91%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.00 0.02 0.02 0.05 0.05 0.10 0.13 0.13 0.12
Accounts Receivable Turnover		 0.00 666.67 1.17 148.58 64.20 204.24 4.63 201.54 81.46 77.52 22.33
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.89 0.93 0.54 1.71 2.28 3.69 3.65 6.45 7.92 9.04 8.76
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.55 312.76 2.46 5.69 1.79 78.89 1.81 4.48 4.71 16.35
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.55 312.76 2.46 5.69 1.79 78.89 1.81 4.48 4.71 16.35
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -27 -23 -20 -21 -6.10 -12 -3.10 -8.48 -17 -24 -25
Invested Capital Turnover		 -0.42 -0.41 -0.34 -0.81 -1.32 -1.33 -1.66 -1.43 -1.27 -1.13 -1.07
Increase / (Decrease) in Invested Capital		 -21 -11 -17 -13 11 12 22 46 40 43 43
Enterprise Value (EV)		 383 1,139 1,476 1,705 1,887 1,661 1,042 627 313 501 193
Market Capitalization		 1,434 2,221 2,676 2,657 2,828 2,293 1,553 1,137 664 874 586
Book Value per Share		 $11.70 $12.25 $13.97 $12.31 $12.45 $9.64 $8.83 $8.92 $6.90 $7.26 $9.38
Tangible Book Value per Share		 $11.70 $12.25 $13.97 $12.31 $12.45 $9.64 $8.83 $8.92 $6.90 $7.26 $9.38
Total Capital		 1,024 1,059 1,180 932 935 621 508 502 334 349 369
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,051 -1,082 -1,200 -953 -941 -633 -511 -510 -351 -373 -394
Capital Expenditures (CapEx)		 1.33 1.10 0.46 0.97 1.33 0.84 0.60 0.88 0.04 0.00 1.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -35 -33 -28 -29 -14 -20 -11 -17 -25 -26 -26
Debt-free Net Working Capital (DFNWC)		 657 644 892 672 684 506 457 476 314 339 361
Net Working Capital (NWC)		 657 644 892 672 684 506 457 476 314 339 361
Net Nonoperating Expense (NNE)		 13 29 5.00 7.32 3.86 4.61 3.97 5.03 5.24 5.69 -0.96
Net Nonoperating Obligations (NNO)		 -1,051 -1,082 -1,200 -953 -941 -633 -511 -510 -351 -373 -394
Total Depreciation and Amortization (D&A)		 -2.65 -4.27 -4.35 -5.54 -5.23 -2.85 -2.54 -1.56 -0.60 -0.21 0.84
Debt-free, Cash-free Net Working Capital to Revenue		 -506.89% -466.81% -725.82% -244.30% -92.74% -83.74% -48.81% -38.24% -53.38% -51.23% -51.20%
Debt-free Net Working Capital to Revenue		 9,386.09% 9,194.89% 22,726.36% 5,621.91% 4,414.01% 2,161.77% 1,947.24% 1,055.38% 662.01% 665.09% 723.29%
Net Working Capital to Revenue		 9,386.09% 9,194.89% 22,726.36% 5,621.91% 4,414.01% 2,161.77% 1,947.24% 1,055.38% 662.01% 665.09% 723.29%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.82) ($1.55) ($0.60) ($0.68) ($0.53) ($0.51) ($0.46) ($0.50) ($0.49) ($0.53) $0.04
Adjusted Weighted Average Basic Shares Outstanding		 88.36M 81.68M 86.19M 77.96M 75.11M 57.52M 60.00M 56.25M 48.37M 41.44M 40.30M
Adjusted Diluted Earnings per Share		 ($0.82) ($1.55) ($0.60) ($0.68) ($0.53) ($0.51) ($0.46) ($0.50) ($0.49) ($0.53) $0.04
Adjusted Weighted Average Diluted Shares Outstanding		 88.36M 81.68M 86.19M 77.96M 75.11M 57.52M 60.00M 56.25M 48.37M 41.44M 41.11M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 87.58M 87.54M 86.43M 84.48M 75.69M 74.56M 64.46M 57.56M 0.00 48.39M 48.11M
Normalized Net Operating Profit after Tax (NOPAT)		 -59 -101 -47 -45 -36 -29 -23 -23 -18 -19 0.46
Normalized NOPAT Margin		 0.00% -1,441.38% 0.00% 0.00% 0.00% -747.91% -291.97% -646.06% -233.44% -460.22% 1.56%
Pre Tax Income Margin		 0.00% -2,222.61% 0.00% 0.00% 0.00% -1,135.71% -417.09% -922.94% -300.00% -692.22% 5.44%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About IDEAYA Biosciences' Financials

When does IDEAYA Biosciences's fiscal year end?

According to the most recent income statement we have on file, IDEAYA Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has IDEAYA Biosciences' net income changed over the last 6 years?

IDEAYA Biosciences' net income appears to be on an upward trend, with a most recent value of -$274.48 million in 2024, rising from -$34.35 million in 2018. The previous period was -$112.96 million in 2023. View IDEAYA Biosciences' forecast to see where analysts expect IDEAYA Biosciences to go next.

What is IDEAYA Biosciences's operating income?
IDEAYA Biosciences's total operating income in 2024 was -$326.98 million, based on the following breakdown:
  • Total Gross Profit: $7 million
  • Total Operating Expenses: $333.98 million
How has IDEAYA Biosciences revenue changed over the last 6 years?

Over the last 6 years, IDEAYA Biosciences' total revenue changed from $0.00 in 2018 to $7 million in 2024, a change of 700,000,000.0%.

How much debt does IDEAYA Biosciences have?

IDEAYA Biosciences' total liabilities were at $64.94 million at the end of 2024, a 130.1% increase from 2023, and a 815.0% increase since 2018.

How much cash does IDEAYA Biosciences have?

In the past 6 years, IDEAYA Biosciences' cash and equivalents has ranged from $20.51 million in 2018 to $157.02 million in 2023, and is currently $84.38 million as of their latest financial filing in 2024.

How has IDEAYA Biosciences' book value per share changed over the last 6 years?

Over the last 6 years, IDEAYA Biosciences' book value per share changed from -51.19 in 2018 to 12.25 in 2024, a change of -123.9%.


Related Companies

This page (NASDAQ:IDYA) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored